Physician profile
Christopher M Ruthruff
NPI 1831144179
$4,603.96
in general payments reported to CMS, 2019-2025
39 companies · $942 in 2025
The $942 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $515 · 2020: $333 · 2021: $249 · 2022: $799 · 2023: $754 · 2024: $1,013 · 2025: $942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,708.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,708.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $881.73 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $428.70 | 2021-2025 | Vraylar |
| Pfizer INC. | $414.78 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $356.87 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $302.32 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Otsuka America Pharmaceutical, INC. | $256.01 | 2020-2025 | Rexulti |
| Glaxosmithkline, LLC. | $222.41 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Dexcom, INC. | $174.20 | 2021-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $160.05 | 2019-2024 | Veozah |
| Lilly USA, LLC | $150.86 | 2022-2024 | Mounjaro, Jardiance, Emgality |
| Lundbeck LLC | $121.33 | 2024-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $102.30 | 2019-2025 | Ajovy |
| Merck Sharp & Dohme LLC | $96.67 | 2019-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| E.R. Squibb & Sons, L.L.C. | $85.53 | 2021-2025 | Eliquis, Camzyos |
| Exact Sciences Corporation | $84.26 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ruthruff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.